Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690932 · ClinicalTrials.gov registry record · Phase 1
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
A Phase 1 study, sponsored by Pyramid Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT05690932: Completed Phase 1 study, sponsored by Pyramid Biosciences.
NCT05690932 is a Phase 1 study that has completed, run by Pyramid Biosciences. The registered enrollment target is 33 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05690932, a Phase 1 study, has completed, sponsored by Pyramid Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a single-dose, two-part, crossover formulation bridging and food effect study to assess the effect of formulation and food on the absorption and bioavailability of PBI-200 in normal, healthy volunteers.
Primary Outcome
Maximum (peak) plasma drug concentration
Interventions
- DRUG PBI-200 Tablet
- DRUG PBI-200 Capsule
- DRUG PBI-200 Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 1 |
What the finished NCT05690932 record still lists
NCT05690932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 3 interventions - of which PBI-200 Tablet is the first listed.
NCT05690932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05690932 about?
NCT05690932 is a clinical study titled "A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers". This is a single-dose, two-part, crossover formulation bridging and food effect study to assess the effect of formulation and food on the absorption and bioavailability of PBI-200 in normal, healthy volunteers.
What is the current status of trial NCT05690932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2022-02-24. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT05690932?
The interventions under investigation include: PBI-200 Tablet (DRUG), PBI-200 Capsule (DRUG), PBI-200 Suspension (DRUG).
Who is sponsoring clinical trial NCT05690932?
This trial is sponsored by Pyramid Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05690932's enrollment target sits among peer trials
33 1280th of 2000 higher than 705 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI